ALLURION TECHNOLOGIES INC SEC Filings

Allurion Technologies, Inc. amended its quarterly report to reflect a reverse stock split and provides details on the previously completed Business Combination with Compute Health Acquisition Corp., related equity recapitalizations, and follow-on financing arrangements. The filing discloses a $37.9 million PIPE investment and multiple convertible note, term loan and revenue-interest financing arrangements with detailed conversion, royalty and reset provisions that could affect future dilution and cash obligations.

The company disclosed prior-period adjustments related to retroactive share restatements from the Business Combination, and identified material weaknesses in internal control over financial reporting with described remedial steps including hiring accounting staff, implementing a new ERP, additional review controls, and engagement of a national accounting firm. The filing also discusses contingent consideration valuation, warrant liabilities, and various debt modifications and covenant features.

Allurion Technologies (ALUR) amended its annual report to reflect a reverse stock split, the close of a business combination with Compute Health, and several financing and restructuring items. The filing discloses continued net operating losses and significant debt, including a $40.0 million upfront Revenue Interest Financing that requires royalty-style payments of up to 6.0% of annual net sales through 2026 and up to 10.0% thereafter through 2030. The company is restating prior financial statements and discloses material weaknesses in disclosure controls and internal control over financial reporting. The Allurion Balloon remains unapproved for commercial sale in the U.S.; the company is conducting an FDA IDE trial (AUDACITY) to support a future PMA. Operationally, Allurion reports commercialization in over 50 countries, a connected patient App and scale, an AI-powered clinic dashboard (Allurion Insights/Allurion Iris AI), and plans to expand its product label, geographic reach, and SaaS offerings. The filing lists numerous risk factors including regulatory, clinical, supply-chain, litigation, liquidity and market-acceptance risks that may materially affect results.

Allurion Technologies (ALUR) amended its annual report to reflect a reverse stock split, the close of a business combination with Compute Health, and several financing and restructuring items. The filing discloses continued net operating losses and significant debt, including a $40.0 million upfront Revenue Interest Financing that requires royalty-style payments of up to 6.0% of annual net sales through 2026 and up to 10.0% thereafter through 2030. The company is restating prior financial statements and discloses material weaknesses in disclosure controls and internal control over financial reporting. The Allurion Balloon remains unapproved for commercial sale in the U.S.; the company is conducting an FDA IDE trial (AUDACITY) to support a future PMA. Operationally, Allurion reports commercialization in over 50 countries, a connected patient App and scale, an AI-powered clinic dashboard (Allurion Insights/Allurion Iris AI), and plans to expand its product label, geographic reach, and SaaS offerings. The filing lists numerous risk factors including regulatory, clinical, supply-chain, litigation, liquidity and market-acceptance risks that may materially affect results.

Allurion Technologies reported operational and financial updates alongside a restatement and remediation efforts for internal control weaknesses. The company is addressing a restatement of prior financial statements and disclosed material weaknesses in internal control over financial reporting while describing steps taken to remediate those weaknesses, including hiring experienced accounting staff, implementing a new ERP system, and engaging a national accounting firm. Management announced a strategic restructuring expected to reduce the workforce by about 70 employees (~65% of staff) with estimated severance-related charges of approximately $1.5 million. Financing activity included multiple private placements and offerings that raised net proceeds of $2.5 million (RTW private placement), $5.8 million (January 2025 offering), and $3.9 million (February 2025 offering), plus a Leavitt placement of $1.3 million. The company described amended revenue interest financing that increases payments from 6.0% up to 10.0% of annual net sales after 2027 and various conversion features tied to PIPE and RTW convertible notes. The filing discloses a pending litigation claim seeking approximately $2.5 million and details product, regulatory, and commercialization initiatives including a GLP-1 program, distribution transitions, and a planned multi-center study in Europe.

Allurion Technologies (ALUR) amended its quarterly report to reflect a prior restatement and to disclose post-business-combination corporate and financing activity. The company completed a business combination with Compute Health and applied a reverse stock split, which changed warrant and share conversion ratios. It disclosed multiple equity and warrant offerings closed in January and February 2025 that raised net proceeds of $5.8 million and $3.9 million, respectively, and additional private placements raising $2.5 million and $1.3 million. The company described amendments to a revenue interest financing agreement that increased revenue-interest rates and related derivative accounting, conversions and debt modifications, and recorded related liabilities and remeasurements. Allurion operates in ~50 countries, provides the Allurion Program and App for remote patient monitoring, and disclosed remediation steps for previously identified internal control weaknesses and an NYSE cure plan.

Allurion Technologies (ALUR) amended its annual report describing strategic, operational and financial risks tied to its post‑merger transition and commercialization of the Allurion Balloon. The company completed a Business Combination with Compute Health and various financings including a July 1, 2024 public offering that raised net proceeds of $15.2 million and multiple private placements. Allurion sells the Allurion Balloon and an AI‑powered Virtual Care Suite (VCS) in over 40 countries but the Balloon is not approved for commercial sale in the U.S. The filing discloses a restatement of prior financial statements, material weaknesses in internal controls, significant debt and revenue‑interest financing with RTW that carries contingent payment rates and covenants. The company states it has incurred losses and expects losses to continue while FDA approval, regulatory compliance, NYSE cure planning, supply, and reimbursement risks remain material.

Allurion Technologies, Inc. filed a Form 12b-25 notifying the SEC that its Form 10-Q for the quarter ended June 30, 2025 could not be filed on time. The notice identifies Brendan M. Gibbons, Chief Legal Officer as the contact and confirms that other periodic reports required over the prior 12 months have been filed. The company indicates it anticipates a significant change in results of operations for the period and includes customary forward-looking risk disclosures about potential adjustments to prior statements, regulatory or legal actions, possible delisting, and timing uncertainties related to completing and filing the 10-Q.

Allurion Technologies, Inc. disclosed accounting issues requiring correction and potential amendments to prior SEC reports, noting the company does not expect the corrections to affect reported revenue, gross margin, operating expenses, or cash. The filing flags risks including additional adjustments to prior statements, a delayed Q2 Quarterly Report for the period ended June 30, 2025, possible SEC or regulatory investigations, potential NYSE delisting, and shareholder litigation. The statement frames these as forward-looking risks while the company completes its evaluation.

Allurion Technologies said it issued a press release covering results for the three and six months ended June 30, 2025 and disclosed a potential accounting error. The company identified a likely miscalculation in non-cash items—Other Comprehensive Income (Loss) and Other Income (Expense)—related to the fair value of its Revenue Interest Financing Agreement (RIFA) and convertible notes, and believes correcting those calculations will likely require restating prior-period financial statements. The company stated these adjustments are non-cash and are not expected to affect revenue, gross margin, operating expenses, or cash. The press release is furnished as Exhibit 99.1.